Markets:

Overview

News

Currencies

International

Treasuries

Clearmind Medicine Inc. - Common Shares (NQ:CMND)

1.990 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EST, Jan 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Clearmind Medicine Inc. - Common Shares

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

Why BSQUARE Shares Are Trading Higher By Around 44%; Here Are 20 Stocks Moving Premarket ↗

October 12, 2023

Gainers OpGen, Inc. (NASDAQ: OPGN) shares rose 432% to $1.79 in pre-market trading. Opgen said on Oct. 6, unit Curetis GMBH received payment of 750,000 euros related to the sale of certain Unyvero A50...

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday ↗

October 12, 2023

Pre-market stock movers are a hot topic among traders on Thursday and we're offering all of the latest coverage this morning!

Via InvestorPlace

Clearmind Medicine to Present at the 8th Annual Dawson James Conference on October 12th

October 05, 2023

From Clearmind Medicine Inc.

Via GlobeNewswire

Why Astra Space Shares Are Trading Lower By 22%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗

October 11, 2023

Gainers Tempest Therapeutics, Inc. (NASDAQ: TPST) shares jumped 1067% to $2.80 after the company released new data demonstrating superiority of TPST-1120 arm across multiple study endpoints in...

Via Benzinga

Aegis Capital Corp. Acted as Exclusive Placement Agent on a $2.25 Million Public Offering for Clearmind Medicine Inc. (NASDAQ:CMND)

September 19, 2023

Via ACCESSWIRE

Demand for Abuse Deterrent Formulation Technology Skyrocketing as Opiate Abuse is on the Rise

September 20, 2023

EQNX::TICKER_START (NASDAQ:NTRB),(NASDAQ:CMND),(NASDAQ:MNMD),(NYSE:CYBN),(NYSE:LLY) EQNX::TICKER_END

Via FinancialNewsMedia

Topics Death Intellectual Property

Psyched: MDMA Trials For PTSD, Congressional Amendments, Scotland's Consumption Site & More ↗

September 18, 2023

Treating PTSD With MDMA Therapy: New Results From MAPS Clinical Study, FDA Submission Next

Via Benzinga

Clearmind Medicine Closes US$2.25 Million Public Offering

September 18, 2023

From Clearmind Medicine Inc.

Via GlobeNewswire

Psychedelics Capital Moves: Beckley Waves Raises $3.3M, Clearmind's $2.25M Public Offering ↗

September 15, 2023

Beckley Waves: $3.3 Million Round To Expand Safe & Legal Access To Psychedelic Therapies

Via Benzinga

Nasdaq Surges 100 Points; First Wave BioPharma Shares Spike Higher ↗

September 14, 2023

U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining more than 100 points on Thursday. The Dow traded up 0.93% to 34,898.47 while the NASDAQ rose 0.75% to 13,917.44....

Via Benzinga

Topics Stocks

Why Clearmind Medicine Shares Are Trading Lower By 53%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗

September 14, 2023

Gainers First Wave BioPharma, Inc. (NASDAQ: FWBI) shares jumped 89.5% to $0.8243 after the company announced license agreement for capeserod from Sanofi.

Via Benzinga

Crude Oil Rises Sharply; BIOLASE Shares Plunge ↗

September 14, 2023

U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining around 100 points on Thursday. The Dow traded up 0.61% to 34,784.94 while the NASDAQ rose 0.71% to 13,911.78. The S&P...

Via Benzinga

Topics Stocks

Why Clearmind Medicine Stock Is Getting Hammered Today ↗

September 14, 2023

Clearmind Medicine Inc (NASDAQ: CMND) shares are trading lower by 53% to $0.18 Thursday morning after the company announced pricing of a $2.25 million public offering. The offering is expected to close...

Via Benzinga

Dow Jumps Over 200 Points; US Producer Prices Rise In August ↗

September 14, 2023

U.S. stocks traded higher this morning, following the release of PPI data. Following the market opening Thursday, the Dow traded up 0.71% to 34,820.58 while the NASDAQ rose 0.27% to 13,849.49. The S&P...

Via Benzinga

Topics Stocks

Clearmind Medicine Announces Pricing of US$2.25 Million Public Offering

September 14, 2023

From Clearmind Medicine Inc.

Via GlobeNewswire

Why Novo Integrated Sciences Shares Are Trading Higher By 9%; Here Are 20 Stocks Moving Premarket ↗

September 14, 2023

Gainers TransCode Therapeutics, Inc. (NASDAQ: RNAZ) shares rose 43.3% to $1.29 in pre-market trading.

Via Benzinga

Psyched: Psilocybin Therapy For Depression, UK Rescheduling, US Policy Reform And More ↗

September 11, 2023

Single Psilocybin Dose 'Significantly' Reduces Major Depression Symptoms, An AI Predictive Model, And UK’s Struggle For Reclassification

Via Benzinga

Topics Artificial Intelligence

Nasdaq Grants SpiSparc, Ltd. Extension To Maintain Listing: +600% Bid Price Surge Needed ↗

September 07, 2023

Specialty clinical-stage biopharma company SciSparc Ltd. (NASDAQ: SPRC) has received a Nasdaq notice granting the company an additional 180-day compliance period until March 4 to regain compliance with...

Via Benzinga

Johns Hopkins Will Work With Clearmind On Alcohol Addiction Research Program ↗

September 06, 2023

Israeli psychedelics biotech Clearmind Medicine (NASDAQ: CMND) has inked a research agreement with Johns Hopkins University School of Medicine (JHU) to conduct the first-in-human Phase I/IIa clinical...

Via Benzinga

Clearmind Medicine Announces Clinical Research Collaboration with Johns Hopkins University to Evaluate CMND-100 in Patients with Alcohol Use Disorder

September 06, 2023

From Clearmind Medicine Inc.

Via GlobeNewswire

Clearmind Medicine Announces Collaboration with CTS Ltd., a Leading Pharmaceutical and Consumer Products Company

August 14, 2023

From Clearmind Medicine Inc.

Via GlobeNewswire

Clearmind Medicine Files Patent Application with USPTO for the Treatment of Dyskinesia; Further Strengthens its Already Robust IP Portfolio

August 01, 2023

From Clearmind Medicine Inc.

Via GlobeNewswire

SciSparc and Clearmind Collaboration Continues to Increase its Patent Portfolio in the Field of Movement Abnormalities in the U.S.

August 01, 2023

From SciSparc Ltd

Via GlobeNewswire

EXCLUSIVE: Clearmind Medicine Files US Patent Application For Dyskinesia Treatment, Strengthening Its IP Portfolio ↗

August 01, 2023

Clearmind Medicine Inc (NASDAQ: CMND) has announced the filing of a provisional patent application for the treatment of Dyskinesia with the United States Patent and Trademark Office (USPTO) as part of...

Via Benzinga

Clearmind Medicine Announces Share-Based Payment for the Company's Consultants

July 17, 2023

From Clearmind Medicine Inc.

Via GlobeNewswire

Dr. Fatima Cody Stanford, Associate Professor of Medicine and Pediatrics at Harvard Medical School, Joins Clearmind Medicine's Scientific Advisory Board

July 11, 2023

From Clearmind Medicine Inc.

Via GlobeNewswire

Clearmind Medicine and SciSparc to Conduct Study Evaluating Combination Treatment for Obesity and Metabolic Syndrome

June 16, 2023

From Clearmind Medicine Inc.

Via GlobeNewswire

SciSparc and Clearmind Medicine to Conduct a Study Evaluating Their Combination Treatment for Obesity and Metabolic Syndrome

June 16, 2023

From SciSparc Ltd

Via GlobeNewswire

Exclusive: Clearmind And SciSparc To Conduct Study Evaluating Psychedelics And CannAmide Based Drug For Treatment Of Obesity And Metabolic Syndrome ↗

June 16, 2023

Clearmind Medicine Inc. (NASDAQ: CMND) (CSE:CMND) (FSE:CWY) announced that as part of the company's ongoing collaboration with SciSparc Ltd.

Via Benzinga

Clearmind Medicine to Host Virtual Investor Conference on Psychedelics for Obesity

June 09, 2023

From Clearmind Medicine Inc.

Via GlobeNewswire

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.